Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
06:30am, Thursday, 06'th Apr 2023
Both Editas Medicine and Bluebird Bio are in a race against their cash runway. Editas is a lot further from commercializing any medicines.
Can This Experimental Gene Therapy Be Enough to Lift Editas Medicine in the Future?
06:00am, Monday, 03'rd Apr 2023
Editas develops genetic therapies to correct naturally occurring errors in a patient's genome that cause genetic diseases. Early clinical trial results for its compound EDIT-301 to treat severe sickle
2 Reasons to Sell Editas Medicine Stock and 1 Reason to Buy It
08:45am, Thursday, 30'th Mar 2023
Editas only has two named therapies currently in its pipeline. Its cash is shrinking and it may need to raise more at some point.
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
08:54pm, Wednesday, 29'th Mar 2023
While it's a common conspiracy theory – and comedic punchline – that medical innovators only seek to manage problems rather than cure them, the reality is that several biotech stocks to buy underg
Why Is Editas (EDIT) Down 21% Since Last Earnings Report?
01:00pm, Friday, 24'th Mar 2023
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
Editas: The Potential Of Gene Editing Technology And The Risks Of A Lackluster Pipeline
10:39pm, Thursday, 23'rd Feb 2023
If EDIT-101 continues to show positive results, it has the potential to become the first-ever gene-editing therapy approved for a genetic disease. Editas has established collaborations with leading bi
Editas (EDIT) Q4 Earnings Miss Estimates, Pipeline in Focus
01:33pm, Thursday, 23'rd Feb 2023
Editas (EDIT) reports a wider loss in the fourth quarter of 2022. The strategic reprioritization, announced last month, is expected to extend the company's cash runway into 2025.
Editas Medicine, Inc. (EDIT) Q4 2022 Earnings Call Transcript
12:43pm, Wednesday, 22'nd Feb 2023
Editas Medicine, Inc. (NASDAQ:EDIT ) Q4 2022 Results Conference Call February 22, 2023 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Gilmore O'Neill - Chief Executive Officer Miche
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
09:02am, Wednesday, 22'nd Feb 2023
Editas (EDIT) delivered earnings and revenue surprises of -4.76% and 43.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023?
11:00am, Thursday, 16'th Feb 2023
Which of these rebounding biotech stocks is the better buy right now?
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
06:45am, Wednesday, 15'th Feb 2023
CAMBRIDGE, Mass., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on W
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?
11:18am, Tuesday, 14'th Feb 2023
Here is how Editas Medicine (EDIT) and Aspira (AWH) have performed compared to their sector so far this year.
Does Editas (EDIT) Have the Potential to Rally 51.55% as Wall Street Analysts Expect?
11:18am, Friday, 10'th Feb 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 51.6% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the positiv
3 No-Brainer Stocks to Buy Right Now for Less Than $25
09:40am, Saturday, 04'th Feb 2023
All three healthcare stocks are showing solid long-term potential.
4 Biotech Stocks Set to Outpace Q4 Earnings Estimates
03:48pm, Friday, 03'rd Feb 2023
Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.
